NMD Pharma treats first patient with the firm's most promising drug candidate
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
NMD Pharma - Inkef capital
Management — NMD Pharma
Biotech completes financing round to advance neuromuscular treatments - EPM Magazine
NMD Pharma treats first patient with the firm's most promising drug candidate
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
News — NMD Pharma
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
NMD Pharma - Inkef capital
Management — NMD Pharma
NMD Pharma - PIR International
Management — NMD Pharma
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Prominent Canadian researcher in Denmark: Why I left a top job in California
Oct 23 | Neuromuscular Drug Development Summit (NMD) | Boston, MA Patch
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Foundations invest DKK 280 million in biomedical company
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Management — NMD Pharma
NMD Pharma A/S | LinkedIn
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
